USA - NYSE:MIR - US60471A1016 - Common Stock
The current stock price of MIR is 27.82 USD. In the past month the price increased by 20.28%. In the past year, price increased by 79.72%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| KEYS | KEYSIGHT TECHNOLOGIES IN | 25.99 | 30.78B | ||
| TDY | TELEDYNE TECHNOLOGIES INC | 24.07 | 23.97B | ||
| TRMB | TRIMBLE INC | 27.01 | 18.70B | ||
| ZBRA | ZEBRA TECHNOLOGIES CORP-CL A | 16.79 | 13.24B | ||
| AEIS | ADVANCED ENERGY INDUSTRIES | 38.93 | 7.36B | ||
| CGNX | COGNEX CORP | 42.55 | 6.72B | ||
| VNT | VONTIER CORP | 11.98 | 5.52B | ||
| BMI | BADGER METER INC | 38.95 | 5.40B | ||
| RAL | RALLIANT CORP | 13.75 | 4.87B | ||
| NOVT | NOVANTA INC | 41.59 | 4.65B | ||
| ITRI | ITRON INC | 17.67 | 4.87B | ||
| OSIS | OSI SYSTEMS INC | 29.15 | 4.67B |
Mirion Technologies, Inc. engages in the provision of radiation safety, science, and medicine. The company is headquartered in Atlanta, Georgia and currently employs 2,860 full-time employees. The company went IPO on 2020-06-29. The firm's segments include Nuclear & Safety and Medical. The Medical includes products and services for radiation therapy, nuclear medicine and personal dosimetry. This segment’s principal product offering is Radiation Therapy Quality Assurance, which includes solutions for calibrating and/or verifying imaging, treatment machine, patient treatment plan, and patient treatment accuracy. The Nuclear & Safety includes products and services focused on addressing critical radiation safety, measurement and analysis applications across nuclear energy, laboratories and research and other industrial markets such as defense. For Nuclear Power Plants (NPPs), it sells products and services for use at any stage of their life (construction, operation, decommissioning and dismantling).
MIRION TECHNOLOGIES INC
1218 Menlo Drive
Atlanta GEORGIA US
CEO: Tom Knott
Employees: 2860
Phone: 17704322744
Mirion Technologies, Inc. engages in the provision of radiation safety, science, and medicine. The company is headquartered in Atlanta, Georgia and currently employs 2,860 full-time employees. The company went IPO on 2020-06-29. The firm's segments include Nuclear & Safety and Medical. The Medical includes products and services for radiation therapy, nuclear medicine and personal dosimetry. This segment’s principal product offering is Radiation Therapy Quality Assurance, which includes solutions for calibrating and/or verifying imaging, treatment machine, patient treatment plan, and patient treatment accuracy. The Nuclear & Safety includes products and services focused on addressing critical radiation safety, measurement and analysis applications across nuclear energy, laboratories and research and other industrial markets such as defense. For Nuclear Power Plants (NPPs), it sells products and services for use at any stage of their life (construction, operation, decommissioning and dismantling).
The current stock price of MIR is 27.82 USD. The price decreased by -5.41% in the last trading session.
MIR does not pay a dividend.
MIR has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
The PE ratio for MIRION TECHNOLOGIES INC (MIR) is 55.64. This is based on the reported non-GAAP earnings per share of 0.5 and the current share price of 27.82 USD.
MIRION TECHNOLOGIES INC (MIR) currently has 2860 employees.
The outstanding short interest for MIRION TECHNOLOGIES INC (MIR) is 10.7% of its float.
ChartMill assigns a technical rating of 10 / 10 to MIR. When comparing the yearly performance of all stocks, MIR is one of the better performing stocks in the market, outperforming 93.82% of all stocks.
ChartMill assigns a fundamental rating of 4 / 10 to MIR. MIR has only an average score on both its financial health and profitability.
Over the last trailing twelve months MIR reported a non-GAAP Earnings per Share(EPS) of 0.5. The EPS increased by 28.21% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 2.94% | ||
| ROA | 0.76% | ||
| ROE | 1.44% | ||
| Debt/Equity | 0.65 |
11 analysts have analysed MIR and the average price target is 26.52 USD. This implies a price decrease of -4.67% is expected in the next year compared to the current price of 27.82.
For the next year, analysts expect an EPS growth of 21.03% and a revenue growth 8.29% for MIR